Acumen Pharmaceuticals Inc
ABOS
Company Profile
Business description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Contact
1210-1220 Washington Street
Suite 210
NewtonMA02465
USAT: +1 617 344-4190
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
61
Stocks News & Analysis
stocks
Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity
Ongoing rate hikes have investors spooked.
stocks
ASX dividend champions: Stocks, ETFs and LICs
Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
stocks
SpaceX’s IPO filing: Big spending, big losses
The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.80 | 9.50 | -0.11% |
| CAC 40 | 8,067.84 | 49.58 | -0.61% |
| DAX 40 | 24,563.84 | 173.40 | -0.70% |
| Dow JONES (US) | 50,009.35 | 645.47 | 1.31% |
| FTSE 100 | 10,390.90 | 41.44 | -0.40% |
| HKSE | 25,386.52 | 264.60 | -1.03% |
| NASDAQ | 26,270.36 | 399.65 | 1.54% |
| Nikkei 225 | 61,684.14 | 1,879.73 | 3.14% |
| NZX 50 Index | 12,878.07 | 117.04 | 0.92% |
| S&P 500 | 7,432.97 | 79.36 | 1.08% |
| S&P/ASX 200 | 8,621.70 | 6.30 | -0.07% |
| SSE Composite Index | 4,077.28 | 84.91 | -2.04% |